Remedy Plan is transforming the field of NAMPT inhibition and was excited to present at Biotech Showcase on January 9th, 2024 at the 42^nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

CEO and Founder Greg Crimmins presented data on RPT1G, a clinical drug candidate for the treatment of solid and hematological malignancies. RPT1G is a small molecule NAMPT inhibitor with a unique, first-in-class mechanism of action that is optimized to preserve the cellular metabolism in healthy cells, while inhibiting activity in malignant cells. This is achieved through hyperbolic inhibition of NAMPT that is fractional and highly tunable. Data presented at JPM, showed that RPT1G selectively killed cancer cells, without the severe on-target toxicities reported for other NAMPT inhibitors.

With a favorable efficacy and tolerability profile in animals, RPT1G will be advancing to the clinic in 2024.

Series A Round

Remedy Plan kicked off their Series A round in January 2024. Please contact [email protected] to learn more about Remedy’s unique approach to NAMPT inhibition with the Remedy Plan team.

Follow Remedy Plan on social media: https://www.linkedin.com/company/remedy-plan/